Sullivan C A, Johnson C A, Roach H, Martin R W, Stewart D K, Morrison J C
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Am J Obstet Gynecol. 1996 May;174(5):1565-8. doi: 10.1016/s0002-9378(96)70607-5.
We attempted to determine whether the antiemetic ondansetron would be more effective than promethazine in treating hyperemesis gravidarum.
Patients with hyperemesis gravidarum who required hospital admission were randomized to receive either intravenous ondansetron (n = 15) or intravenous promethazine (n = 15) in a double-blind manner. Severity of disease was determined by electrolyte status, weight loss, ketonuria, and prior use of outpatient antiemetics. Outcome variables included degree of nausea, weight gain during treatment, days of hospitalization, and number of medication doses.
In this preliminary investigation ondansetron offered no advantage when compared with promethazine in the relief of nausea, weight gain, days of hospitalization (4.5 +/- 2.3 vs 4.5 +/- 1.5), and total doses of medication per hospitalization (2.1 +/- 1.2 vs 1.9 +/- 1.3).
This preliminary trial of ondansetron demonstrated no benefit over promethazine in patients hospitalized for hyperemesis gravidarum.
我们试图确定抗呕吐药物昂丹司琼在治疗妊娠剧吐方面是否比异丙嗪更有效。
因妊娠剧吐需住院治疗的患者被随机分为两组，以双盲方式分别接受静脉注射昂丹司琼（n = 15）或静脉注射异丙嗪（n = 15）。通过电解质状态、体重减轻、酮尿症以及先前使用门诊抗呕吐药物的情况来确定疾病的严重程度。结果变量包括恶心程度、治疗期间体重增加情况、住院天数以及用药剂量。
在这项初步研究中，与异丙嗪相比，昂丹司琼在缓解恶心、体重增加、住院天数（4.5±2.3对4.5±1.5）以及每次住院的总用药剂量（2.1±1.2对1.9±1.3）方面均无优势。
对于因妊娠剧吐住院的患者，这项关于昂丹司琼的初步试验表明其并不比异丙嗪更具优势。
